Table 2.
Extent of ASPD Symptoms | |||||
---|---|---|---|---|---|
FΔ | df | P | R2Δ | β | |
Model 1: | |||||
Step 1 | |||||
Male gender | 13.73 | 1, 106 | .000 | .12 | .34*** |
Step 2 | |||||
Early clinical risk | 3.55 | 2,104 | .03* | .06 | |
Early clinical risk vs longitudinal comparison | .28* | ||||
Early clinical risk vs cross-sectional comparison | .28** | ||||
| |||||
Model 2: | |||||
Step 1 | |||||
Male gender | 13.73 | 1, 106 | .000 | .12 | .34*** |
Step 2 | |||||
Childhood abuse | 5.07 | 1,105 | .03 | .04 | .22* |
Model 3: Evaluating Mediation by Childhood Abuse | |||||
Step 1 | |||||
Gendera | 13.73 | 1,106 | .000 | .12 | .34*** |
Step 2 | |||||
Childhood abuse | 5.07 | 1, 105 | .03 | .04 | .20* |
Step 3 | |||||
Early clinical risk | 4.59 | 1, 104 | .04 | .04 | .20* |
Note. N = 108.